Robert Jan Lamers (CEO) will be present at Phacilitate Cell & Gene Therapy Europe 2017 in Berlin where Janneke Meulenberg, COO, will join the speaker panel on Wednesday 20st of September.
Arthrogen's COO, Janneke Meulenberg, will present Wednesday September 13 a case study on: Production Platforms for RA Gene Therapy Applications at the 'Cell and Gene Therapy Manufacturing' conference in London
Appeal by the Dutch Arthritis Association: http://www.reumafonds.nl/informatie-voor-doelgroepen/patienten/help-mee/neem-deel-aan-onderzoek
Arthrogen to be present at the EULAR Annual European Congress of Rheumatology, Madrid June 14-17, 2017
Arthrogen’s CEO Robert Jan Lamers to present at the May 22-23, 2017 BioEquity, Paris
Arthrogen to be present at the American Society of Gene & Cell Therapy, ASGCT annual meeting, Washington, DC May 10-13, 2017
Arthrogen’s CEO Robert Jan Lamers to present at the May 3, 2017 Investment Summit for Advanced Therapies, London
Arthrogen in the news: http://labiotech.eu/arthrogen-gene-therapy-rheumatoid-arthritis/
February 16, 2017
Today, biopharmaceutical company Arthrogen announced the approval for the ART-I02 gene therapy clinical phase Ib study in patients with rheumatoid arthritis. The clinical trial will focus on rheumatoid arthritis patients who, despite multiple treatments with existing medicines, still suffer from inflamed joints. The new approach is unique in that it aims to stimulate the local production of an anti-inflammatory protein within the inflamed joint by means of a single treatment. A virus is used to deliver a piece of genetic material into the joint, which will then produce its own anti-inflammatory protein in the inflamed area, only when needed. It is expected that one single injection will have a long-lasting effect. This initial trial will be used to examine safety and the first signs of effects. The study will be executed by the Centre for Human Drug Research (CHDR) in Leiden in close collaboration with University Medical Centers in the Netherlands.. Read more
Empty Capsids and Macrophage Inhibition/Depletion Increase rAAV Transgene Expression in Joints of Both Healthy and Arthritic Mice. The researchers present evidence demonstrating the synergistic enhancement of transgene expression achieved when the two pre-treatments were combined. Read more
Arthrogen’s COO Janneke Meulenberg PhD. and CEO Robert Jan Lamers will be present at the Cell & Gene Therapy World 2017 in Miami, January 17-20 2017. On Thursday January 19 at 10.50-11.30am Janneke Meulenberg will present “AAV-mediated gene therapy for rheumatoid arthritis: toward clinical trials with ART-I02” at the Biotech Showcase Session. For meeting requests please use the Phacilitate meeting system, the contact form on www.arthrogen.nl or the Arthrogen LinkedIn page.